Sökning: WFRF:(Kamby Claus)
> (2006-2009) >
Improved outcome fr...
Improved outcome from substituting methotrexate with epirubicin : results from a randomised comparison of CMF versus CEF in patients with primary breast cancer
-
- Ejlertsen, Bent (författare)
- Department of Oncology, Copenhagen University Hospital, Bldg. 5012, Rigshospitalet, 9. Blegdamsvej, DK-2100 Copenhagen, Denmark
-
- Mouridsen, Henning T (författare)
- Department of Oncology, Copenhagen University Hospital, Bldg. 5012, Rigshospitalet, 9. Blegdamsvej, DK-2100 Copenhagen, Denmark, DBCG Registry, Copenhagen, Denmark
-
- Jensen, Maj-Britt (författare)
- DBCG Registry, Copenhagen, Denmark
-
visa fler...
-
- Andersen, Jørn (författare)
- Department of Oncology, Aarhus Hospital, Aarhus University, Denmark
-
- Cold, Søren (författare)
- Department of Oncology, Esbjerg County Hospital, Esbjerg, Denmark
-
- Edlund, Per (författare)
- Uppsala universitet,Centrum för klinisk forskning, Gävleborg,Department of Oncology, Odense University Hospital, Odense, Denmark
-
- Ewertz, Marianne (författare)
- Department of Oncology, Gaavle County Hospital, Gaavle, Sweden
-
- Jensen, Brita B (författare)
- Karolinska Institutet,Department of Oncology, Aalborg Hospital, Aarhus University, Denmark,Radiumhemmet, Stockholm Oncology, Karolinska Institute, University Hospital, Stockholm, Sweden
-
- Kamby, Claus (författare)
- Department of Oncology, Herlev University Hospital, Herlev, Denmark
-
- Nordenskjöld, Bo (författare)
- Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Onkologiska kliniken US
-
Bergh, Jonas (författare)
-
visa färre...
-
Department of Oncology, Copenhagen University Hospital, Bldg 5012, Rigshospitalet, 9. Blegdamsvej, DK-2100 Copenhagen, Denmark Department of Oncology, Copenhagen University Hospital, Bldg. 5012, Rigshospitalet, 9. Blegdamsvej, DK-2100 Copenhagen, Denmark, DBCG Registry, Copenhagen, Denmark (creator_code:org_t)
- Elsevier BV, 2007
- 2007
- Engelska.
-
Ingår i: European Journal of Cancer. - : Elsevier BV. - 0959-8049 .- 1879-0852. ; 43:5, s. 877-884
- Relaterad länk:
-
http://www.ncbi.nlm....
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- We compared the efficacy of CEF (cyclophosphamide, epirubicin, and fluorouracil) against CMF (cyclophosphamide, methotrexate, and fluorouracil) in moderate or high risk breast cancer patients. We randomly assigned 1224 patients with completely resected unilateral breast cancer to receive nine cycles of three-weekly intravenous CMF or CEF. Patients were encouraged to take part in a parallel trial comparing oral pamidronate 150 mg twice daily for 4 years versus control (data not shown). Substitution of methotrexate with epirubicin significantly reduced the unadjusted hazard for disease-free survival (DFS) by 16% (hazard ratio 0.84; 95% CI; 0.71-0.99) and for overall survival by 21% (hazard ratio 0.79; 95% CI; 0.66-0.94). The risk of secondary leukaemia and congestive heart failure was similar in the two groups. Overall CEF was superior over CMF in terms of DFS and OS in patients with operable breast cancer without subsequent increase in late toxicities.
Nyckelord
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*therapeutic use
- Breast Neoplasms/*drug therapy
- Cyclophosphamide/administration & dosage
- Cytarabine/administration & dosage
- Epirubicin/administration & dosage
- Female
- Fluorouracil/administration & dosage
- Humans
- Methotrexate/administration & dosage
- Middle Aged
- Treatment Outcome
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Ejlertsen, Bent
-
Mouridsen, Henni ...
-
Jensen, Maj-Brit ...
-
Andersen, Jørn
-
Cold, Søren
-
Edlund, Per
-
visa fler...
-
Ewertz, Marianne
-
Jensen, Brita B
-
Kamby, Claus
-
Nordenskjöld, Bo
-
Bergh, Jonas
-
visa färre...
- Artiklar i publikationen
-
European Journal ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet
-
Linköpings universitet